Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 3
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 2(1)
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04342156Phase 3Withdrawn

Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19

Role: collaborator

NCT00213044Phase 1Completed

A Randomized, Controlled, Cross-Over Trial of Safety of Vaginal Use of Carraguard by HIV-Infected Women

Role: collaborator

NCT00213031Phase 2Completed

Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide

Role: collaborator

All 3 trials loaded